Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics
SRP-9005 (rAAVrh74.MHCK7.hSGCG) is an adeno-associated virus vector gene therapy delivering the human SGCG gene, which encodes gamma-sarcoglycan, for single intravenous infusion. It is studied in limb-girdle muscular dystrophy.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06952686 | Phase 3 | Muscular Dystrophies, Limb-Girdle | Withdrawn | SRPT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Muscular Dystrophies, Limb-Girdle
Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.
See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SRPT catalysts and pipeline →